Strategies for recombinant allergen vaccines and fruitful results from first clinical studies
- PMID: 16701144
- DOI: 10.1016/j.iac.2006.02.001
Strategies for recombinant allergen vaccines and fruitful results from first clinical studies
Abstract
Recombinant DNA technology has delivered the prospect of a new generation of preparations for allergen-specific immunotherapy. The first clinical studies with recombinant allergens have yielded encouraging results, suggesting that there is a good chance that such preparations will become available for use in the routine management of allergic disease.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
